EnvoyAI Partner:


Resonance WITH catchline
if_290_279051.png
Year Founded: 2003
if_search_244366.png
Area of Focus/Specialty: We quantify iron levels in the liver, heart, pancreas, spleen, and bone marrow. We also assess fat (VLFF, PDFF) in the above organs (barring bone marrow).
if__location_1964213.png
Company Headquarters: Perth, Australia

Resonance Health

About Resonance Health

Resonance Health is an Australian healthcare company specializing in the development and delivery of non-invasive medical imaging software and services. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing highest quality quantitative measurements essential in the management of particular diseases. Our products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical companies in their clinical trials. Resonance Health’s dedication to scientific rigour in the development and implementation of its analysis services has enabled it to achieve regulatory clearances on a number of products (SaMD) in the US, Europe and Australia. This rigour extends to a philosophy of quality management in all aspects of our operations. Resonance Health carries ISO 13485:2016 certification.

Resonance’s flagship product FerriScan® is the global gold-standard for liver iron concentration quantification, and has become established in many international ‘Standards of Care’ for Thalassemia and Sickle Cell Disease.

FerriScan®’s proprietary technology recently has been applied in training neural networks to develop our new product FerriSmart®, the world’s first and only regulatory-cleared Artificial Intelligence tool for the quantification of liver iron concentration.

if__location_1964213.png

Reference Sites:

To date, FerriScan® and FerriSmart® have been established in over 470 hospitals across the globe, including:

  • Alfred l. DuPont Hospital for Children
  • Children’s Hospitla Boston
  • Children’s Healthcare of Atlanta
  • Children’s Hospital of Philadelphia
  • Johns Hopkins Hospital
  • Massachusetts General Hospital
  • Hospital of the University of Pennsylvania
  • Toronto General Hospital
  • Guy’s and St Thomas’ NHS Foundation Trust
  • Kings College Hospital
  • St Mary’s Hospital – Imperial College Healthcare
  • Ulm University Hospital
  • Ege University
  • Bach Mai Hospital
if_newspaper_193067.png

Given the recent development and FDA clearance of FerriSmart, there has currently been no published work to date, however FerriSmart was validated via the FerriScan technology which has many.

End-User Testimonials

Professor of Paediatric Haematology

"FerriSmart is easy to use and gives almost instant liver iron concentration results without the need for time consuming data analysis. We have used it with patients with both moderate and severe iron loading. The fact that it has been trained from FerriScan data gives us confidence in the results."

Dr Yesim Aydinok, Professor of Paediatric Haematology, Ege University Children’s Hospital, Turkey.

Senior Radiologist

“FerriSmart is easy to use, just upload data then wait a few second for the result. Access to the result is simple, with quick service support.”

Dr Trang Nguyen Ngoc, Senior Radiologist (Department of Radiology BMH), Bach Mai Hospital, Vietnam

Resonance Health Leadership
AlisonLaws-2

Alison Laws

Chief Executive Officer

agha-shahzad-1

Agha Shahzad

Chief Financial Officer and Company Secretary

Celine-Royet-new-1

Celine Royet

Regulatory Affairs Manager

Tim-St-Pierre-1

Prof Tim St Pierre

Chief Scientific Officer

wenjie-1

Dr Wenjie Pang

Technical and Research Manager

Resonance Health Machine | FerriSmart

Resonance Health is directly responsible for product and clinical representations

  • ferrismart report

FerriSmart® is a stand-alone software application that automatically analyses multi-slice, spin-echo MRI data sets encompassing the abdomen to determine the signal decay rate (R2) that is used to characterize iron loading in the liver, which is then transformed by a defined calibration curve to provide a quantitative measure of liver iron concentrations in vivo.

  • Modality: MR
  • Anatomic Target (Body Part): Liver
  • Body Region (ex. Chest, Head/Neck, Cardiac, etc.): Abdominal
  • Applicable Study Types: MRI Study
  • Desired Input: FerriScan Standardized Acquisition MR DICOM Images
  • Provided Output: DICOM file with an Embedded PDF report
  • FDA Status: Received 510(k) clearance from the FDA on 01 December 2018.
  • Intended Use:  For the measurement of R2 and iron concentration in the liver from MRI scans.
  • Indications for Use: FerriSmart® is indicated to:
    • Measure liver iron concentration in individuals with confirmed or suspected systemic iron overload;
    • Monitor liver iron burden in transfusion dependent thalassemia patients and patients with sickle cell disease receiving blood transfusions;
    • Aid in the identification and monitoring of non-transfusion-dependent thalassemia patients receiving therapy with deferasirox.